09Jul 2024
Radiotherapy vs. surgery post chemoimmunotherapy in stage III lung cancer: Analysis

Radiotherapy vs. surgery post chemoimmunotherapy in stage III lung cancer: Analysis

This study compared outcomes of neoadjuvant chemoimmunotherapy followed by surgery or radiotherapy in stage III non-small-cell lung cancer (NSCLC) patients. Before matching, surgery showed superior progression-free survival (PFS) over radiotherapy. After propensity score matching, PFS was similar between groups, with radiotherapy offering comparable efficacy and manageable safety profiles. Subgroup analysis suggested stage IIIA patients may benefit more from surgery. Grade 3–4 treatment-related adverse events were slightly higher with radiotherapy. These findings propose radiotherapy as a potential alternative for NSCLC patients unsuitable for surgery post-chemoimmunotherapy, urging further prospective studies for validation and treatment optimization.

  • #pulmonology

Like

Save

Share